PDF 2017 DOWNLOADS



18th JANUARY, AFTERNOON SESSION
     14:15    Welcome and introduction (G. Di Perri)
     SESSION I - CLINICAL PHARMACOLOGY OF HAART (Chair: M. Galli, M. Kurowski)
     14:30    Clinical pharmacology of integrase inhibitors (M. Boffito) download
     15:00    Booster and boosted in the same pill: pharmacological considerations (S. Bonora) download
     15:30    N(t)RTIs: the evolving scenario (G. Di Perri) download
     16:00    Plenary discussion
     16:15    Coffee break
     16:30    PK variability of antiretrovirals in the clinical setting: which lesson for clinicians? (D. Cattaneo) download
     17:00    Clinical notes: TDM of antiretrovirals in 2017 (Chair G. Di Perri)
                         - why? (S. Bonora) download
                         - when? (C. Alcantarini, C. Montrucchio) download
                         - how? (A. D'Avolio) download
     18:00    Closing Day 1 Remarks


19th JANUARY, MORNING SESSION
    SESSION I - LOOKING FORWARD NEW STANDARDS (Chair: G. Di Perri, S. Khoo)
     09:00    The pipeline: long-acting agents and new drugs (C. Flexner) download
     09:30    Nanoformulations of antivirals (A. Owen) download
     10:00    Role of clinical pharmacology in developing countries (M. Lamorde) download
     10:30    Plenary discussion
     10:45    Coffee break
     SESSION II - DRUG-DRUG INTERACTIONS: HIV VS HCV (Chair: C. Flexner, R. Garraffo)
     11:00    Drug-drug interactions in the HIV-positive aging patient (C. Marzolini) download
     11:30    Clinical notes: a new wave of HIV drug-drug interactions (N. Pagani) download
     12:00    Drug drug interactions of Hep-C drugs: data gaps and perspectives (S. Bonora) download
     12:30    New tools to predict and study DDIs (M. Siccardi) download
     13:00    Plenary discussion
     13:10    Lunch


19th JANUARY, AFTERNOON SESSION
    SESSION III - HCV TREATMENT: OPEN QUESTIONS (Chair: D. Back, M. Rizzetto, G.M. Saracco)
     14:00    Who are the difficult-to-treat HCV patients nowadays? (S. Bhagani) download
     14:30    Which role for virologist in DAAs era? (F. Ceccherini Silberstein) download
     15:00    Which opportunities for HCV generics? (A. Hill) download
     15:30    Plenary discussion
     15:45    Coffee break
     16:00    How severe liver disease affect PK of Hep-C drugs? (G. Di Perri) download
     16:30    Beyond HCV cure: which reversibility of liver damage? (M. Puoti) download
     17:00    Clinical notes: Management of HIV/HCV co-infected patient in real life (L. Marinaro) download
     17:30    Plenary discussion
     17:45    Closing Day 2 Remarks


20th JANUARY, MORNING SESSION
    SESSION I - THE HIDDEN WARS (Chair: M. Andreoni, V. Ghisetti, G. Nunnari)
     09:00    Pharmacokinetics and pharmacodynamics of antiretrovirals in lymphatic and gut tissues (C. Fletcher)
     09:30    PK of antiretrovirals in pregnancy and therapeutic consequences (A. Colbers) download
     10:00    Shortening anti-HCV therapy: to what extent? (C.F. Perno) download
     10:30    Plenary discussion
     10:45    Coffee break
    SESSION II- CNS AND HIV/HCV (Chair: A. Antinori)
     11:00    Neurocognitive impairment in HCV chronic infection (S. Letendre) download
     11:30    Neuroefficacy vs neurotoxicity of ARVs (A. Calcagno) download
     12:00    Clinical notes: management of HAART in patients with HAND (P. Cinque)
     12:30    Plenary discussion
     12:45    Key learnings 2017 (G. Di Perri)
     13:15    CME test